Van Lanschot Kempen Logo
  • Home
  • Solutions
  • News & knowledge
  • About us
Jun 2014
Joint Bookrunner
41.7 million
Accelerated Bookbuild Offering


Ablynx is a listed Belgian biotech focused on the discovery and development of innovative products for serious diseases, including inflammation, haematology and oncology

  • Ablynx placed 4,908,332 new shares to fund ongoing and future clinical trials
  • Kempen & Co acted as Joint Bookrunner and generated significant demand resulting in the upsizing of the deal from an initial €30m at launch to a total of €41.7m

Fully focused on your future

Private Banking

  • Offices
  • Business professionals
  • Executives
  • Doctors
  • Entrepreneurs
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions

Investment Management

Investment Banking

© Van Lanschot Kempen 2023
Privacy & cookies